Seres Therapeutics, Inc. Impairment of Long-Lived Assets to be Disposed of
Seres Therapeutics, Inc. (MCRB) reported Impairment of Long-Lived Assets to be Disposed of of $5.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf · last filed 2026-08-05
- Seres Therapeutics, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2026-06-30 was $5.81M.
- Seres Therapeutics, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2025-12-31 was $0.00.
- Seres Therapeutics, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2025-09-30 was $0.00.
- Seres Therapeutics, Inc. impairment of long-lived assets to be disposed of for the quarter ending 2025-06-30 was $0.00.
- Seres Therapeutics, Inc. impairment of long-lived assets to be disposed of for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Seres Therapeutics, Inc. impairment of long-lived assets to be disposed of for fiscal 2024 was $3.27M.
- Seres Therapeutics, Inc. impairment of long-lived assets to be disposed of for fiscal 2023 was $0.00.
- Seres Therapeutics, Inc. impairment of long-lived assets to be disposed of for fiscal 2022 was $0.00.
| Period end | Impairment of Long-Lived Assets to be Disposed of 3 month | Impairment of Long-Lived Assets to be Disposed of 6 month | Impairment of Long-Lived Assets to be Disposed of 9 month | Impairment of Long-Lived Assets to be Disposed of 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.81M 10-Q · filed 2026-08-05 | $5.81M 10-Q · filed 2026-08-05 | ||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2026-08-05 | $0.00 10-Q · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 10-Q · filed 2026-08-05 | $0.00 10-Q · filed 2026-08-05 | $0.00 derived: sum of 3 quarters · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $3.27M 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $3.27M 10-Q · filed 2025-11-05 | $3.27M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $3.27M 10-Q · filed 2025-08-06 | $3.27M derived: sum of 3 quarters · filed 2026-03-12 | $3.27M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $3.27M 10-Q · filed 2025-05-07 | $3.27M derived: sum of 2 quarters · filed 2026-03-12 | $3.27M derived: sum of 3 quarters · filed 2026-03-12 | $3.27M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $0.00 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $0.00 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |